Boston Therapeutics, Inc. (BTHE-OTCQB), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Meng Hee Tan, M.D. to serve as its Consulting Medical Director and a member of its Medical Advisory Team. Dr. Tan is expected to help guide the Company's development of its diabetes-related treatments.
Dr. Tan is a professor of internal medicine at the University of Michigan and attending physician in metabolism, endocrinology, and diabetes at the University of Michigan Health System. A member of the American Diabetes Association and the American College of Endocrinology, he is the author or coauthor of more than 110 peer-reviewed publications in the area of diabetes and carbohydrate metabolism. He is a past senior medical director of the Diabetes Endocrine Platform Team at Eli Lilly. He received an M.D. from Dalhousie University.